Kazia Therapeutics Limited (NASDAQ:KZIA) Short Interest Up 110.7% in January

Kazia Therapeutics Limited (NASDAQ:KZIA) was the target of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 11,800 shares, an increase of 110.7% from the December 31st total of 5,600 shares. Based on an average daily trading volume, of 102,700 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.4% of the shares of the stock are short sold.

Hedge Funds Weigh In On Kazia Therapeutics

An institutional investor recently bought a new position in Kazia Therapeutics stock. MAI Capital Management acquired a new stake in shares of Kazia Therapeutics Limited (NASDAQ:KZIA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 1,363,894 shares of the company’s stock, valued at approximately $586,000. MAI Capital Management owned approximately 51.66% of Kazia Therapeutics as of its most recent SEC filing. Institutional investors own 30.89% of the company’s stock.

Kazia Therapeutics Stock Down 20.3 %

NASDAQ KZIA traded down $0.39 during trading on Friday, hitting $1.52. 1,735,239 shares of the company’s stock were exchanged, compared to its average volume of 5,365,462. Kazia Therapeutics has a fifty-two week low of $1.32 and a fifty-two week high of $15.80. The stock’s 50 day moving average price is $2.89 and its two-hundred day moving average price is $3.88.

Kazia Therapeutics Company Profile

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company’s lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3.